632 related articles for article (PubMed ID: 27679482)
1. Exosome secretion is a key pathway for clearance of pathological TDP-43.
Iguchi Y; Eid L; Parent M; Soucy G; Bareil C; Riku Y; Kawai K; Takagi S; Yoshida M; Katsuno M; Sobue G; Julien JP
Brain; 2016 Dec; 139(Pt 12):3187-3201. PubMed ID: 27679482
[TBL] [Abstract][Full Text] [Related]
2. Withania somnifera Reverses Transactive Response DNA Binding Protein 43 Proteinopathy in a Mouse Model of Amyotrophic Lateral Sclerosis/Frontotemporal Lobar Degeneration.
Dutta K; Patel P; Rahimian R; Phaneuf D; Julien JP
Neurotherapeutics; 2017 Apr; 14(2):447-462. PubMed ID: 27928708
[TBL] [Abstract][Full Text] [Related]
3. Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease.
Dinkins MB; Dasgupta S; Wang G; Zhu G; Bieberich E
Neurobiol Aging; 2014 Aug; 35(8):1792-800. PubMed ID: 24650793
[TBL] [Abstract][Full Text] [Related]
4. The heat shock response plays an important role in TDP-43 clearance: evidence for dysfunction in amyotrophic lateral sclerosis.
Chen HJ; Mitchell JC; Novoselov S; Miller J; Nishimura AL; Scotter EL; Vance CA; Cheetham ME; Shaw CE
Brain; 2016 May; 139(Pt 5):1417-32. PubMed ID: 26936937
[TBL] [Abstract][Full Text] [Related]
5. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments.
Swarup V; Phaneuf D; Bareil C; Robertson J; Rouleau GA; Kriz J; Julien JP
Brain; 2011 Sep; 134(Pt 9):2610-26. PubMed ID: 21752789
[TBL] [Abstract][Full Text] [Related]
6. Exposure to ALS-FTD-CSF generates TDP-43 aggregates in glioblastoma cells through exosomes and TNTs-like structure.
Ding X; Ma M; Teng J; Teng RK; Zhou S; Yin J; Fonkem E; Huang JH; Wu E; Wang X
Oncotarget; 2015 Sep; 6(27):24178-91. PubMed ID: 26172304
[TBL] [Abstract][Full Text] [Related]
7. Divergent phenotypes in mutant TDP-43 transgenic mice highlight potential confounds in TDP-43 transgenic modeling.
D'Alton S; Altshuler M; Cannon A; Dickson DW; Petrucelli L; Lewis J
PLoS One; 2014; 9(1):e86513. PubMed ID: 24466128
[TBL] [Abstract][Full Text] [Related]
8. [The molecular mechanisms of intracellular TDP-43 aggregates].
Nonaka T; Arai T; Hasegawa M
Brain Nerve; 2009 Nov; 61(11):1292-300. PubMed ID: 19938686
[TBL] [Abstract][Full Text] [Related]
9. Praja1 RING-finger E3 ubiquitin ligase suppresses neuronal cytoplasmic TDP-43 aggregate formation.
Watabe K; Kato Y; Sakuma M; Murata M; Niida-Kawaguchi M; Takemura T; Hanagata N; Tada M; Kakita A; Shibata N
Neuropathology; 2020 Dec; 40(6):570-586. PubMed ID: 32686212
[TBL] [Abstract][Full Text] [Related]
10. Transthyretin attenuates TDP-43 proteinopathy by autophagy activation via ATF4 in FTLD-TDP.
Chu YP; Jin LW; Wang LC; Ho PC; Wei WY; Tsai KJ
Brain; 2023 May; 146(5):2089-2106. PubMed ID: 36355566
[TBL] [Abstract][Full Text] [Related]
11. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD.
Kumar S; Phaneuf D; Cordeau P; Boutej H; Kriz J; Julien JP
Mol Neurodegener; 2021 Jan; 16(1):1. PubMed ID: 33413517
[TBL] [Abstract][Full Text] [Related]
12. Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS.
Ke YD; van Hummel A; Stevens CH; Gladbach A; Ippati S; Bi M; Lee WS; Krüger S; van der Hoven J; Volkerling A; Bongers A; Halliday G; Haass NK; Kiernan M; Delerue F; Ittner LM
Acta Neuropathol; 2015 Nov; 130(5):661-78. PubMed ID: 26437864
[TBL] [Abstract][Full Text] [Related]
13. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes.
Tan RH; Kril JJ; Fatima M; McGeachie A; McCann H; Shepherd C; Forrest SL; Affleck A; Kwok JB; Hodges JR; Kiernan MC; Halliday GM
Brain; 2015 Oct; 138(Pt 10):3110-22. PubMed ID: 26231953
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of C-terminal fragments of transactive response DNA-binding protein 43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice.
Medina DX; Orr ME; Oddo S
Neurobiol Aging; 2014 Jan; 35(1):79-87. PubMed ID: 23954172
[TBL] [Abstract][Full Text] [Related]
15. Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse.
Dinkins MB; Enasko J; Hernandez C; Wang G; Kong J; Helwa I; Liu Y; Terry AV; Bieberich E
J Neurosci; 2016 Aug; 36(33):8653-67. PubMed ID: 27535912
[TBL] [Abstract][Full Text] [Related]
16. Abnormal regenerative responses and impaired axonal outgrowth after nerve crush in TDP-43 transgenic mouse models of amyotrophic lateral sclerosis.
Swarup V; Audet JN; Phaneuf D; Kriz J; Julien JP
J Neurosci; 2012 Dec; 32(50):18186-95. PubMed ID: 23238732
[TBL] [Abstract][Full Text] [Related]
17. Cognitive decline typical of frontotemporal lobar degeneration in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43.
Caccamo A; Majumder S; Oddo S
Am J Pathol; 2012 Jan; 180(1):293-302. PubMed ID: 22067910
[TBL] [Abstract][Full Text] [Related]
18. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?
Hergesheimer RC; Chami AA; de Assis DR; Vourc'h P; Andres CR; Corcia P; Lanznaster D; Blasco H
Brain; 2019 May; 142(5):1176-1194. PubMed ID: 30938443
[TBL] [Abstract][Full Text] [Related]
19. Platinum Nanoparticles Enhance Exosome Release in Human Lung Epithelial Adenocarcinoma Cancer Cells (A549): Oxidative Stress and the Ceramide Pathway are Key Players.
Gurunathan S; Kang MH; Jeyaraj M; Kim JH
Int J Nanomedicine; 2021; 16():515-538. PubMed ID: 33519199
[TBL] [Abstract][Full Text] [Related]
20. [A new dementia group caused by TDP-43 abnormality].
Arai T; Hosokawa M; Hasegawa M; Akiyama H; Asada T
Seishin Shinkeigaku Zasshi; 2011; 113(6):574-83. PubMed ID: 21815469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
